Table 2. Prevention measures in place before and after the implementation of ALMANACH.
| BASELINE | ROUTINE | CRS | CTS | |
|---|---|---|---|---|
| Danger signs§checked (at least one) # (%) | 6 (1.5) | N/A | 75 (41.4)* | N/A |
| Tot. 2–60 months # (%) | 404 (100.0) | 181 (100.0) | ||
| Weighed # (%) | 13 (3.2) | 6324 (99.7%) | 181 (100.0)* | 177 (97.8)* |
| Tot. 2–60 months # (%) | 404 (100.0) | 6343 (100.0) | 181 (100.0) | 181 (100.0) |
| MUAC measured # (%) | 0 (0.0) | N/A | 37 (23.1)* | N/A |
| Tot. ≥ 6–60 months | 352 (87.1) | 160 (88.4) | ||
| Malnourishment detected # (%) | 0 (0.0) | 132 (2.1) | 5 (2.7)* | 0 (0.0) |
| 404 (100.0) | 6343 (100.0) | 181 (100.0) | 181 (100.0) | |
| Albendazole received # (%) | 14 (5.2) | 1‘792 (31.3%) | 117 (95.1)* | 130 (94.2)* |
| Tot. ≥ 12–60 months | 270 (66.9) | 5‘723 (90.2%) | 123 (67.9) | 138 (76.2) |
| Vitamin A received # (%) | 0 (0) | 1‘900 (41.9%) | 148 (92.5)* | 149 (90.8)* |
| Tot. ≥ 6–60 months | 352 (87.1) | 4‘538 (71.5%) | 160 (88.4) | 164 (90.6) |
| Vaccination status checked # (%) | 70 (32.4) | N/A | 92 (100.0)* | 83 (94.3)* |
| Tot. ≥ 3–23 months | 216 (53.5) | N/A | 92 (50.8) | 88 (48.6) |
*significant (p < .05) in comparison to the baseline survey
§ IMCI’s Danger signs include: convulsion currently or the recent past, unconsciousness/lethargy, vomit everything, inability to drink or to be breastfed